Do analysts rate DXR or OBIO?

Orchestra BioMed has a consensus price target of $13.60, suggesting a potential upside of 228.11%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Orchestra BioMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has higher valuation and earnings, DXR or OBIO?

Daxor has higher earnings, but lower revenue than Orchestra BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor $10.30M 6.04 N/A N/A N/A Orchestra BioMed $32.72M 7.58 -$52.70M -$0.97 N/A

Does the media refer more to DXR or OBIO?

In the previous week, Daxor had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for Daxor and 1 mentions for Orchestra BioMed. Daxor's average media sentiment score of 0.67 beat Orchestra BioMed's score of 0.00 indicating that Daxor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DXR or CNXU?

Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 152.53%. Given Conexeu Sciences' higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Conexeu Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, DXR or CNXU?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor $10.30M 6.04 N/A N/A N/A Conexeu Sciences N/A N/A N/A -$0.11 N/A

Is DXR or CNXU more profitable?

Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Conexeu Sciences N/A N/A N/A

Does the media prefer DXR or CNXU?

In the previous week, Conexeu Sciences had 5 more articles in the media than Daxor. MarketBeat recorded 8 mentions for Conexeu Sciences and 3 mentions for Daxor. Daxor's average media sentiment score of 0.67 beat Conexeu Sciences' score of 0.12 indicating that Daxor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Conexeu Sciences 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FOCL or DXR?

FocalTherics presently has a consensus target price of $9.00, suggesting a potential upside of 46.34%. Given FocalTherics' higher possible upside, equities research analysts plainly believe FocalTherics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FocalTherics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, FOCL or DXR?

Daxor has lower revenue, but higher earnings than FocalTherics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $74.07M 3.11 -$29.25M -$0.81 N/A Daxor $10.30M 6.04 N/A N/A N/A

Is FOCL or DXR more profitable?

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% Daxor N/A N/A N/A

Does the media prefer FOCL or DXR?

In the previous week, FocalTherics had 1 more articles in the media than Daxor. MarketBeat recorded 4 mentions for FocalTherics and 3 mentions for Daxor. Daxor's average media sentiment score of 0.67 beat FocalTherics' score of 0.65 indicating that Daxor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EMBC or DXR?

Embecta currently has a consensus price target of $11.00, suggesting a potential upside of 198.51%. Given Embecta's higher possible upside, equities research analysts clearly believe Embecta is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 2 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.60 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, EMBC or DXR?

Embecta has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.20 $95.40M $1.90 1.94 Daxor $10.30M 6.04 N/A N/A N/A

Is EMBC or DXR more profitable?

Embecta has a net margin of 10.73% compared to Daxor's net margin of 0.00%. Daxor's return on equity of 0.00% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Daxor N/A N/A N/A

Does the media favor EMBC or DXR?

In the previous week, Embecta had 35 more articles in the media than Daxor. MarketBeat recorded 38 mentions for Embecta and 3 mentions for Daxor. Daxor's average media sentiment score of 0.67 beat Embecta's score of 0.02 indicating that Daxor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 1 Positive mention(s) 36 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INFU or DXR?

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 62.25%. Given InfuSystem's stronger consensus rating and higher possible upside, equities research analysts clearly believe InfuSystem is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InfuSystem 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation & earnings, INFU or DXR?

InfuSystem has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $142.40M 1.31 $870K $0.38 24.33 Daxor $10.30M 6.04 N/A N/A N/A

Is INFU or DXR more profitable?

InfuSystem has a net margin of 1.12% compared to Daxor's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Daxor N/A N/A N/A

Does the media favor INFU or DXR?

In the previous week, Daxor had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Daxor and 1 mentions for InfuSystem. Daxor's average media sentiment score of 0.67 beat InfuSystem's score of 0.00 indicating that Daxor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Daxor (DXR) Competitors

$10.66 +0.16 (+1.48%)

As of 03:05 PM Eastern

Compare

DXR vs. OBIO, CNXU, FOCL, EMBC, and INFU

Should you buy Daxor stock or one of its competitors? MarketBeat compares Daxor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Daxor include Orchestra BioMed (OBIO), Conexeu Sciences (CNXU), FocalTherics (FOCL), Embecta (EMBC), and InfuSystem (INFU).

How does Daxor compare to Orchestra BioMed?

Daxor (NASDAQ:DXR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Daxor has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Daxor's return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Orchestra BioMed	-166.96%	-157.46%	-60.18%

In the previous week, Daxor had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for Daxor and 1 mentions for Orchestra BioMed. Daxor's average media sentiment score of 0.67 beat Orchestra BioMed's score of 0.00 indicating that Daxor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has a consensus price target of $13.60, suggesting a potential upside of 228.11%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Daxor has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Daxor has higher earnings, but lower revenue than Orchestra BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$10.30M	6.04	N/A	N/A	N/A
Orchestra BioMed	$32.72M	7.58	-$52.70M	-$0.97	N/A

1.3% of Daxor shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 51.5% of Daxor shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Orchestra BioMed beats Daxor on 7 of the 13 factors compared between the two stocks.

How does Daxor compare to Conexeu Sciences?

Daxor (NASDAQ:DXR) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$10.30M	6.04	N/A	N/A	N/A
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 152.53%. Given Conexeu Sciences' higher probable upside, analysts clearly believe Conexeu Sciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

1.3% of Daxor shares are owned by institutional investors. 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Conexeu Sciences had 5 more articles in the media than Daxor. MarketBeat recorded 8 mentions for Conexeu Sciences and 3 mentions for Daxor. Daxor's average media sentiment score of 0.67 beat Conexeu Sciences' score of 0.12 indicating that Daxor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Conexeu Sciences	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Conexeu Sciences	N/A	N/A	N/A

Summary

Daxor beats Conexeu Sciences on 4 of the 6 factors compared between the two stocks.

How does Daxor compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
Daxor	N/A	N/A	N/A

In the previous week, FocalTherics had 1 more articles in the media than Daxor. MarketBeat recorded 4 mentions for FocalTherics and 3 mentions for Daxor. Daxor's average media sentiment score of 0.67 beat FocalTherics' score of 0.65 indicating that Daxor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FocalTherics has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Daxor has lower revenue, but higher earnings than FocalTherics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$74.07M	3.11	-$29.25M	-$0.81	N/A
Daxor	$10.30M	6.04	N/A	N/A	N/A

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

FocalTherics presently has a consensus target price of $9.00, suggesting a potential upside of 46.34%. Given FocalTherics' higher possible upside, equities research analysts plainly believe FocalTherics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Daxor beats FocalTherics on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to Embecta?

Embecta (NASDAQ:EMBC) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Embecta pays an annual dividend of $0.04 per share and has a dividend yield of 1.1%. Daxor pays an annual dividend of $0.03 per share and has a dividend yield of 0.3%. Embecta pays out 2.1% of its earnings in the form of a dividend.

Embecta has a net margin of 10.73% compared to Daxor's net margin of 0.00%. Daxor's return on equity of 0.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Daxor	N/A	N/A	N/A

Embecta has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Daxor has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Embecta currently has a consensus price target of $11.00, suggesting a potential upside of 198.51%. Given Embecta's higher possible upside, equities research analysts clearly believe Embecta is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

93.8% of Embecta shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 51.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Embecta has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.20	$95.40M	$1.90	1.94
Daxor	$10.30M	6.04	N/A	N/A	N/A

In the previous week, Embecta had 35 more articles in the media than Daxor. MarketBeat recorded 38 mentions for Embecta and 3 mentions for Daxor. Daxor's average media sentiment score of 0.67 beat Embecta's score of 0.02 indicating that Daxor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	1 Positive mention(s)	36 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Embecta beats Daxor on 8 of the 15 factors compared between the two stocks.

How does Daxor compare to InfuSystem?

InfuSystem (NYSE:INFU) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Daxor had 2 more articles in the media than InfuSystem. MarketBeat recorded 3 mentions for Daxor and 1 mentions for InfuSystem. Daxor's average media sentiment score of 0.67 beat InfuSystem's score of 0.00 indicating that Daxor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Daxor	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

InfuSystem has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$142.40M	1.31	$870K	$0.38	24.33
Daxor	$10.30M	6.04	N/A	N/A	N/A

InfuSystem presently has a consensus price target of $15.00, suggesting a potential upside of 62.25%. Given InfuSystem's stronger consensus rating and higher possible upside, equities research analysts clearly believe InfuSystem is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

InfuSystem has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Daxor has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

InfuSystem has a net margin of 1.12% compared to Daxor's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Daxor	N/A	N/A	N/A

Summary

InfuSystem beats Daxor on 9 of the 13 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$62.20M	$5.71B	$6.81B	$12.70B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	N/A	23.64	281.58	25.14
Price / Sales	6.04	58.86	571.14	79.78
Price / Cash	N/A	32.53	28.64	34.82
Price / Book	N/A	6.53	11.03	6.20
Net Income	N/A	$151.15M	$3.48B	$347.60M
7 Day Performance	-0.14%	3.20%	0.47%	0.81%
1 Month Performance	1.33%	-1.27%	-4.24%	-3.65%
1 Year Performance	12.75%	5.02%	63.03%	20.30%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	1.4945 of 5 stars	$10.66 +1.5%	N/A	+12.9%	$62.20M	$10.30M	N/A	37	Positive News Gap Up
OBIO Orchestra BioMed	3.2436 of 5 stars	$3.99 +5.0%	$13.60 +240.9%	+63.1%	$238.93M	$32.72M	N/A	4
CNXU Conexeu Sciences	3.1644 of 5 stars	$8.83 +11.9%	$20.00 +126.5%	N/A	$236.27M	N/A	N/A	4	News Coverage Gap Up
FOCL FocalTherics	3.4783 of 5 stars	$6.14 -1.8%	$9.00 +46.6%	N/A	$230.14M	$74.07M	N/A	230	Positive News Analyst Upgrade Gap Down
EMBC Embecta	4.2858 of 5 stars	$3.66 -0.5%	$11.00 +200.5%	-63.5%	$218.33M	$1.08B	1.93	1,850	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors

DXR vs. OBIO, CNXU, FOCL, EMBC, and INFU

How does Daxor compare to Orchestra BioMed?

Summary

How does Daxor compare to Conexeu Sciences?

Summary

How does Daxor compare to FocalTherics?

Summary

How does Daxor compare to Embecta?

Summary

How does Daxor compare to InfuSystem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Daxor (DXR) Competitors

DXR vs. OBIO, CNXU, FOCL, EMBC, and INFU

How does Daxor compare to Orchestra BioMed?

Is DXR or OBIO more profitable?

Does the media refer more to DXR or OBIO?

Do analysts rate DXR or OBIO?

Which has more volatility & risk, DXR or OBIO?

Which has higher valuation and earnings, DXR or OBIO?

Do insiders & institutionals hold more shares of DXR or OBIO?

Summary

How does Daxor compare to Conexeu Sciences?

Which has higher earnings & valuation, DXR or CNXU?

Do analysts rate DXR or CNXU?

Do insiders & institutionals hold more shares of DXR or CNXU?

Does the media prefer DXR or CNXU?

Is DXR or CNXU more profitable?

Summary

How does Daxor compare to FocalTherics?

Is FOCL or DXR more profitable?

Does the media prefer FOCL or DXR?

Which has more volatility & risk, FOCL or DXR?

Which has better valuation and earnings, FOCL or DXR?

Do insiders and institutionals have more ownership in FOCL or DXR?

Do analysts prefer FOCL or DXR?

Summary

How does Daxor compare to Embecta?

Is EMBC or DXR a better dividend stock?

Is EMBC or DXR more profitable?

Which has more volatility & risk, EMBC or DXR?

Do analysts prefer EMBC or DXR?

Do insiders and institutionals have more ownership in EMBC or DXR?

Which has higher valuation & earnings, EMBC or DXR?

Does the media favor EMBC or DXR?

Summary

How does Daxor compare to InfuSystem?

Does the media favor INFU or DXR?

Do insiders and institutionals hold more shares of INFU or DXR?

Which has better valuation & earnings, INFU or DXR?

Do analysts prefer INFU or DXR?

Which has more volatility and risk, INFU or DXR?

Is INFU or DXR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools